Breaking Finance News

RBC Capital recorded Puma Biotech. (NASDAQ:PBYI), hiking its price target to $60.00 earlier today

RBC Capital bumped up the target of Puma Biotech. (NASDAQ:PBYI) to $60.00 indicating a possible downside of -0.20%.

On 03/02/2017, RBC Capital released a statement about Puma Biotech. (NASDAQ:PBYI) reduced the target price from $48.00 to $17.00 that suggested a downside of -0.55%.

Yesterday Puma Biotech. (NASDAQ:PBYI) traded -1.66% lower at $74.95. The company’s 50-day moving average is $108.65 and its 200-day moving average is $77.13. The last stock close price is down 61.23% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 409,669 shares of Puma Biotech. exchanged hands, down from an avg. volume of 894,239

Performance Chart

Puma Biotech. (NASDAQ:PBYI)

With a total market value of $0, Puma Biotech. has with a one year low of $28.35 and a one year high of $127.02 .

A total of 6 firms have reported on the company. 2 brokerages rating the stock a strong buy, four equity analysts rating the company a buy, two equity analysts rating the company a hold, zero analysts rating the company a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $95.50.

About Puma Biotech. (NASDAQ:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.